A CLINICAL STAGE COMPANY BY 2022

Multiple programs of “sole-in-class” drug-candidates:

​

• The 1st regulator of Golgi trafficking: the KIF20-A inhibitor DIACC 2010, firstly in blood cancers

• The 1st immunotherapy targeting membrane-driven CD4 T cells anergia: the anti-PLA2G1B DIACC1010 in cancers and infectious diseases with partial or total CD4 immunodeficiency